» Phase II Data On Lilly's Antibody Show It Affects Amyloid Beta, A Protein Believed To Be Associated With Alzheimer's Disease
Eli Lilly and Company (NYSE: LLY) announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta monoclonal antibody for the treatment of mild to moderate…